AstraZeneca sees higher 2022 sales, but COVID boost waning
AstraZeneca sees higher 2022 sales, but COVID boost waning
February 10, 2022
AstraZeneca forecast higher 2022 sales and raised its annual dividend for the first time in a decade, but warned that the boost from COVID-19 products would fall.
Post A Comment:
0 comments:
Leave a comment. Thanks!